ATC Group: R06AE05 Meclozine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R06AE05 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R06 Antihistamines for systemic use
3 R06A Antihistamines for systemic use
4 R06AE Piperazine derivatives
5 R06AE05 Meclozine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 50 mg
RECTAL - Rectal 50 mg

Active ingredients in R06AE05

Active Ingredient Description
Meclozine

Meclizine is a first generation antihistamine that is used largely to treat vertigo and motion sickness.

Medicines in this ATC group

Brazil (BR)

Finland (FI)

France (FR)

Hong Kong (HK)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Romania (RO)

Spain (ES)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.